Jansen G, Westerhof G R, Jarmuszewski M J, Kathmann I, Rijksen G, Schornagel J H
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
J Biol Chem. 1990 Oct 25;265(30):18272-7.
This study reports the isolation and characterization of a variant of the human CCRF-CEM leukemia cell line that overproduces the carrier protein responsible for the uptake of reduced folates and the folate analogue methotrexate. The variant was obtained by adapting CCRF-CEM cells for prolonged times to stepwise decreasing concentrations of 5-formyltetrahydrofolate as the sole folate source in the cell culture medium. From cells that were grown on less than 1 nM 5-formyl-tetrahydrofolate, a variant (CEM-7A) was isolated exhibiting a 95-fold increased Vmax for [3H]methotrexate influx compared to parental CCRF-CEM cells. The values for influx Km, efflux t0.5, and Ki for inhibition by other folate (analogue) compounds were unchanged. Affinity labeling of the carrier with an N-hydroxysuccinimide ester of [3H]methotrexate demonstrate an approximately 30-fold increased incorporation of [3H] methotrexate in CEM-7A cells. This suggests that the up-regulation of [3H]methotrexate influx is not only due to an increased amount of carrier protein, but also to an increased rate of carrier translocation or an improved cooperativity between carrier protein molecules. Incubation for 1 h at 37 degrees C of CEM-7A cells with a concentration of 5-formyltetrahydrofolate or 5-methyltetrahydrofolate in the physiological range (25 nM) resulted in a 7-fold decline in [3H]methotrexate influx. This down-regulation during incubations with 5-formyltetrahydrofolate or 5-methyltetrahydrofolate could be prevented by either the addition of 10-25 nM of the lipophilic antifolate trimetrexate or by preincubating CEM-7A cells with 25 nM methotrexate. The down-regulatory effect was specifically induced by reduced folates since incubation of CEM-7A cells with 25 nM of either methotrexate, 10-ethyl-10-deazaaminopterin, aminopterin, or folic acid, or a mixture of purines and thymidine, had no effect on [3H]methotrexate influx. Similarly, these down-regulatory effects on [3H]methotrexate transport by 5-formyltetrahydrofolate, and its reversal by trimetrexate or methotrexate, were also observed, though to a lower extent, for parental CCRF-CEM cells grown in folate-depleted medium rather than in standard medium containing high folate concentrations. These results indicate that mediation of reduced folate/methotrexate transport can occur at reduced folate concentrations in the physiological range, and suggest that the intracellular folate content may be a critical determinant in the regulation of methotrexate transport.
本研究报告了人CCRF - CEM白血病细胞系一个变体的分离与特性,该变体过量产生负责摄取还原型叶酸和叶酸类似物甲氨蝶呤的载体蛋白。该变体是通过使CCRF - CEM细胞在细胞培养基中以逐步降低浓度的5 - 甲酰四氢叶酸作为唯一叶酸来源进行长时间适应而获得的。从在低于1 nM 5 - 甲酰四氢叶酸上生长的细胞中,分离出一个变体(CEM - 7A),与亲本CCRF - CEM细胞相比,其[³H]甲氨蝶呤流入的Vmax增加了95倍。流入Km、流出t0.5以及其他叶酸(类似物)化合物抑制的Ki值未发生变化。用[³H]甲氨蝶呤的N - 羟基琥珀酰亚胺酯对载体进行亲和标记表明,CEM - 7A细胞中[³H]甲氨蝶呤的掺入增加了约30倍。这表明[³H]甲氨蝶呤流入的上调不仅是由于载体蛋白量的增加,还由于载体转运速率的提高或载体蛋白分子之间协同性的改善。将CEM - 7A细胞在37℃下用生理范围内(25 nM)浓度的5 - 甲酰四氢叶酸或5 - 甲基四氢叶酸孵育1小时,导致[³H]甲氨蝶呤流入下降7倍。在用5 - 甲酰四氢叶酸或5 - 甲基四氢叶酸孵育期间的这种下调可通过添加10 - 25 nM亲脂性抗叶酸药三甲曲沙或通过用25 nM甲氨蝶呤预孵育CEM - 7A细胞来预防。下调作用是由还原型叶酸特异性诱导的,因为将CEM - 7A细胞与25 nM甲氨蝶呤、10 - 乙基 - 10 - 脱氮氨基蝶呤、氨基蝶呤或叶酸,或嘌呤和胸苷的混合物孵育对[³H]甲氨蝶呤流入没有影响。同样,对于在叶酸缺乏培养基而非含有高叶酸浓度的标准培养基中生长的亲本CCRF - CEM细胞,也观察到了5 - 甲酰四氢叶酸对[³H]甲氨蝶呤转运的这些下调作用及其被三甲曲沙或甲氨蝶呤逆转的情况,尽管程度较低。这些结果表明,在生理范围内降低的叶酸浓度下可发生还原型叶酸/甲氨蝶呤转运的介导作用,并表明细胞内叶酸含量可能是甲氨蝶呤转运调节中的一个关键决定因素。